News and Announcements
SUDA LTD Signs Term Sheet to Acquire Anti-Cancer Agent
- Published June 20, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD (ASX:SUD), a leader in oro-mucosal drug delivery, has announce that is has signed a binding Memorandum of Understanding (MoU) with UK-based Aluztra Bio Ltd to acquire the global intellectual property relating to a novel anti-cancer agent.
KEY TAKEAWAYS:
- Under the terms of the MoU, SUDA has up to six months to complete its due diligence on Anagrelide before entering a definitive agreement.
- Aluztra and its partner, Cancer Research UK, will be entitled to a low single-digit percentage royalty on direct net sales or a share of income generated by SUDA from commercialisation of an oro-mucosal spray of Anagrelide.
- Anagrelide is currently used as an anti-thrombotic agent to reduce elevated levels of platelets.
- Scientists have identified that platelets also provide essential growth factors that nourish cancer cells and enable them to take hold and develop into tumours. Hence, those patients with the highest platelet numbers are least likely to survive.
- Anagrelide has the potential to be developed as an effective anti-cancer agent, but is fundamentally limited in its current formulation by cardio-stimulatory side-effects.
- An oromucosal spray formulation of Anagrelide could minimise these side-effects by avoiding first-pass metabolism of the active drug in the liver.
- The global market for cancer drugs has grown to more than $100 billion in annual sales.
Mr Stephen Carter, SUDA’s CEO and Managing Director, commented: “Anagrelide is an interesting opportunity for SUDA. We believe that the use of our proprietary OroMistâ technology to formulate an oral spray of Anagrelide with efficient oro-mucosal absorption of the active agent could represent a compelling new strategy for the treatment of solid tumours. There is substantial data in the literature to support the theory that non-enteral administration of Anagrelide could avoid the dose-limiting cardio-toxicity associated with first-pass metabolism of this potentially very effective anti-cancer agent.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
